Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment
Abstract Migraine is a debilitating headache disorder. The disease has neurovascular origin and migraine attacks can be elicited by vasodilative neuropeptides such as alpha calcitonin gene-related peptide (αCGRP). Antagonizing CGRP actions in migraine patients has proven clinically efficient. Here,...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-84547-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594761404383232 |
|---|---|
| author | Jens Bjelke Kristensen Lisbeth Elster Morten Lundh Borja Ballarín-González Flora Alexopoulou Martin Kræmer Ditte Marie Jensen Ulrike Leurs Jens Christian Nielsen Henrik H. Hansen Kristian A. Haanes Matilda Degn |
| author_facet | Jens Bjelke Kristensen Lisbeth Elster Morten Lundh Borja Ballarín-González Flora Alexopoulou Martin Kræmer Ditte Marie Jensen Ulrike Leurs Jens Christian Nielsen Henrik H. Hansen Kristian A. Haanes Matilda Degn |
| author_sort | Jens Bjelke Kristensen |
| collection | DOAJ |
| description | Abstract Migraine is a debilitating headache disorder. The disease has neurovascular origin and migraine attacks can be elicited by vasodilative neuropeptides such as alpha calcitonin gene-related peptide (αCGRP). Antagonizing CGRP actions in migraine patients has proven clinically efficient. Here, we present a pipeline for development of a peptide-based hCGRP receptor antagonist with increased half-life capable of antagonising the vasodilatory effect of hαCGRP. A series of hαCGRP8-37 analogues carrying a C18-or C20-diacid lipidation was screened for their antagonism against the hCGRP receptor. hαCGRP8-37 analogues with a C20-diacid were 2-6 fold more potent than analogues conjugated with a C18-diacid. Half-life of hαCGRP8-37 analogues carrying a C20-diacid was estimated in mice in a pilot study (n = 1–2). Half-lives ranged from 7.3 to 13.7 h. An hαCGRP8-37 analogue conjugated with a C20 diacid at position 25 was subjected to an amino acid substitution scan to identify mutations that could further enhance hCGRP receptor antagonism. Substituting alanine with serine at position 36 resulted in a ~ 4 fold gain of potency. Vasodilative actions of hαCGRP were successfully antagonized by hαCGRP8-37 analogues carrying a C20 diacid at position 25. Our findings demonstrate that lipidation can improve hαCGRP8-37 pharmacokinetics while maintaining hαCGRP antagonism, thus demonstrating potential for a peptide-based migraine treatment strategy. |
| format | Article |
| id | doaj-art-56ec284cf0144f279fbe06f0f44442c9 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-56ec284cf0144f279fbe06f0f44442c92025-01-19T12:20:31ZengNature PortfolioScientific Reports2045-23222025-01-0115111510.1038/s41598-024-84547-1Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatmentJens Bjelke Kristensen0Lisbeth Elster1Morten Lundh2Borja Ballarín-González3Flora Alexopoulou4Martin Kræmer5Ditte Marie Jensen6Ulrike Leurs7Jens Christian Nielsen8Henrik H. Hansen9Kristian A. Haanes10Matilda Degn11Gubra ApSGubra ApSGubra ApSGubra ApSGubra ApSGubra ApSGubra ApSGubra ApSGubra ApSGubra ApSSensory Biology Unit, Translational Research Centre, Copenhagen University Hospital - RigshospitaletGubra ApSAbstract Migraine is a debilitating headache disorder. The disease has neurovascular origin and migraine attacks can be elicited by vasodilative neuropeptides such as alpha calcitonin gene-related peptide (αCGRP). Antagonizing CGRP actions in migraine patients has proven clinically efficient. Here, we present a pipeline for development of a peptide-based hCGRP receptor antagonist with increased half-life capable of antagonising the vasodilatory effect of hαCGRP. A series of hαCGRP8-37 analogues carrying a C18-or C20-diacid lipidation was screened for their antagonism against the hCGRP receptor. hαCGRP8-37 analogues with a C20-diacid were 2-6 fold more potent than analogues conjugated with a C18-diacid. Half-life of hαCGRP8-37 analogues carrying a C20-diacid was estimated in mice in a pilot study (n = 1–2). Half-lives ranged from 7.3 to 13.7 h. An hαCGRP8-37 analogue conjugated with a C20 diacid at position 25 was subjected to an amino acid substitution scan to identify mutations that could further enhance hCGRP receptor antagonism. Substituting alanine with serine at position 36 resulted in a ~ 4 fold gain of potency. Vasodilative actions of hαCGRP were successfully antagonized by hαCGRP8-37 analogues carrying a C20 diacid at position 25. Our findings demonstrate that lipidation can improve hαCGRP8-37 pharmacokinetics while maintaining hαCGRP antagonism, thus demonstrating potential for a peptide-based migraine treatment strategy.https://doi.org/10.1038/s41598-024-84547-1 |
| spellingShingle | Jens Bjelke Kristensen Lisbeth Elster Morten Lundh Borja Ballarín-González Flora Alexopoulou Martin Kræmer Ditte Marie Jensen Ulrike Leurs Jens Christian Nielsen Henrik H. Hansen Kristian A. Haanes Matilda Degn Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment Scientific Reports |
| title | Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment |
| title_full | Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment |
| title_fullStr | Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment |
| title_full_unstemmed | Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment |
| title_short | Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment |
| title_sort | pipeline for development of acylated peptide based cgrp receptor antagonist with extended half life for migraine treatment |
| url | https://doi.org/10.1038/s41598-024-84547-1 |
| work_keys_str_mv | AT jensbjelkekristensen pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment AT lisbethelster pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment AT mortenlundh pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment AT borjaballaringonzalez pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment AT floraalexopoulou pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment AT martinkræmer pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment AT dittemariejensen pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment AT ulrikeleurs pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment AT jenschristiannielsen pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment AT henrikhhansen pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment AT kristianahaanes pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment AT matildadegn pipelinefordevelopmentofacylatedpeptidebasedcgrpreceptorantagonistwithextendedhalflifeformigrainetreatment |